UK Launches Chickenpox Vaccination for Young Children

For the first time, young children in the United Kingdom can receive the chickenpox vaccine through the NHS, marking a significant advancement in public health.

The new vaccine, known as MMRV, combines the chickenpox vaccine with the existing MMR shot, which protects against measles, mumps, and rubella. This combined vaccine will be administered at the ages of 12 and 18 months, with opportunities for children up to six years old to catch up on missed doses.

Health specialists anticipate that the introduction of MMRV will significantly decrease the number of families impacted by chickenpox each year and help avert severe cases of the illness.

Previously, parents faced the burden of spending up to £200 for private vaccination to shield their children from this infection.

Implementation Details

Beginning on January 1, the MMRV vaccine will be integrated into the standard immunization schedule for children in England, Wales, and Northern Ireland. Scotland has also announced that it will commence its rollout in early January.

Chickenpox is prevalent among young children, characterized by an itchy rash that develops into blisters before crusting over. The condition can cause discomfort and may lead to additional symptoms such as fever and muscle pain, leaving children feeling unwell for several days.

The infection spreads rapidly, with around 90% of children under ten years old contracting chickenpox at some stage. Consequently, it is not uncommon for children to miss a week of school or nursery due to the illness.

Health Risks and Expert Opinions

However, the disease can escalate to more severe health complications, according to Dr. Gayatri Amirthalingam, the deputy director of immunisation at the UK Health Security Agency. She stated, “For some infants, young children, and even adults, chickenpox can pose serious health risks, resulting in hospitalizations and, in rare cases, fatalities.”

Potential complications include bacterial infections of the blisters and, in rare instances, conditions such as encephalitis, pneumonia, and stroke.

Young infants and adults face a higher risk of serious illness from chickenpox, while pregnant women are particularly vulnerable due to the potential risks to both their health and that of their unborn children.

Maria Horton shared her experience of her daughter Beth, who was only two-and-a-half years old when she suffered a stroke after contracting chickenpox. “She collapsed, and her arm and leg went limp before she began to have a seizure,” said Horton, a resident of Plymouth.

Vaccination Benefits and Future Outlook

Beth continues to deal with the consequences of her illness, facing challenges such as limited use of her right hand and ongoing pain. Horton expressed regret about not vaccinating her daughter sooner, stating, “If I could turn back time and prevent something dreadful from occurring, I certainly would.”

Dr. Claire Fuller, the national medical director for NHS England, called the introduction of the chickenpox vaccine a “significant advancement for children and their families”. Health Secretary Wes Streeting encouraged all parents to embrace the vaccination program, labeling the rollout as a “historic achievement in safeguarding the health of our children” against an illness that frequently leads to hospitalizations.

Countries such as the United States, Canada, Australia, and Germany have safely employed the MMRV vaccine for decades, resulting in marked declines in chickenpox cases and associated serious health issues.

The chickenpox component of the MMRV vaccine has demonstrated remarkable efficacy, with a success rate of approximately 97% following two doses, providing long-lasting protection.

Financial Implications and Recommendations

The UK has been slow to adopt this vaccination program for various reasons, including concerns regarding costs and potential increases in shingles cases. However, long-term studies from the US have shown no significant rise in shingles incidence post-vaccination.

Recent data highlights the financial burden of chickenpox on the UK healthcare system, with an estimated £24 million lost annually in income and productivity due to childhood cases. NHS England also estimates that the vaccine’s introduction could result in savings of £15 million per year in treatment costs.

In light of these considerations, the Joint Committee on Vaccination and Immunisation (JCVI) recommended the NHS’s adoption of the vaccine in November 2023. Streeting noted, “Families will benefit both financially and in terms of time, escaping lost income from time off work and no longer needing to pay for private vaccinations.”

The Royal College of Paediatrics and Child Health hailed the rollout as “excellent news,” while the Royal College of GPs affirmed the safety and efficacy of all NHS childhood vaccines, emphasizing that vaccinations are among the most crucial health measures parents can take for their children.

In the new vaccination schedule, children born after January 1, 2026, will automatically receive two doses of the MMRV vaccine at 12 months and 18 months of age. A catch-up campaign will be available for older children, offering one or two doses based on their birth dates.

Children aged six or older as of December 31, 2025, will not qualify for the MMRV vaccine, as they are likely to have already contracted chickenpox. General practitioners will reach out to families to arrange appointments as vaccination dates approach.